Group 1 - A class action has been filed against Petco Health and Wellness Company, Inc. for misleading investors regarding its business prospects during the period from January 14, 2021, to June 5, 2025 [1][2] - Allegations include that Petco's pandemic-related growth was unsustainable and that the company overstated its ability to deliver sustainable, profitable growth [2] - The complaint highlights that the true scope of issues affecting Petco's business model and sales metrics was downplayed by the defendants [2] Group 2 - Shareholders may participate in the class action and can contact Robbins LLP if they wish to serve as lead plaintiff [3] - The representation in the class action is on a contingency fee basis, meaning shareholders pay no fees or expenses [4] - Robbins LLP has been dedicated to helping shareholders recover losses and improve corporate governance since 2002 [4]

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. for allegedly misleading investors regarding the safety of its gene therapy drug, ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [1][2]. Allegations - The lawsuit claims that Sarepta failed to disclose significant safety risks associated with ELEVIDYS, including the inability of trial protocols to detect severe side effects and the potential for adverse events to halt recruitment and dosing in clinical trials [2]. - Specific allegations include that the severity of adverse events would attract regulatory scrutiny and increase risks surrounding the therapy's approvals [2]. Stock Price Impact - Following a safety update on March 18, 2025, which reported a patient death after ELEVIDYS treatment, Sarepta's stock price dropped by $27.81, or 27.44%, closing at $73.54 [3]. - On June 15, 2025, after disclosing a second patient death due to acute liver failure and announcing a suspension of shipments for non-ambulatory patients, the stock fell by $15.24, or 42.12%, closing at $20.91 [3]. - The FDA's investigation announcement on June 24, 2025, regarding the risk of acute liver failure led to an additional stock price decline of $1.52, or 8.01%, closing at $17.46 [4]. Class Action Participation - Shareholders interested in participating as lead plaintiffs in the class action must file a motion by August 25, 2025, although participation is not required to be eligible for recovery [5].

SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- Leading shareholder rights law firm Johnson Fistel, PLLP announces an investigation into potential breaches of fiduciary duties by current and former directors and officers of Masimo Corporation (NASDAQ: MASI). The investigation centers on whether Masimo’s leadership failed to uphold their responsibilities to shareholders and may have violated corporate governance obligations. Why Is Johnson Fistel Investigating Masimo Corporation?The investigation follows a cour ...

NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Avis Budget Group, Inc. (NASDAQ:CAR) on behalf of long-term stockholders following a class action complaint that was filed against Avis on April 25, 2025 with a Class Period from February 16, 2024 and February 10, 2025. Our investigation concerns whether the board of directors of Avis have breached their fiduciary duties to the company. The l ...

NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Napco Security Technologies, Inc. (NASDAQ: NSSC) on behalf of long-term stockholders following a class action complaint that was filed against NAPCO on April 25, 2025 with a Class Period from February 5, 2024, to February 3, 2025. Our investigation concerns whether the board of directors of NAPCO have breached their fiduciary duties to the co ...

HALIFAX, Nova Scotia, June 26, 2025 (GLOBE NEWSWIRE) -- Erdene Resource Development Corporation (TSX:ERD | MSE:ERDN) (“Erdene” or the “Company”) is pleased to announce its shareholders voted in favour of all items of business brought before them at the Company's Annual and Special Meeting of Shareholders (“Meeting”) held on June 25, 2025 in Halifax, Nova Scotia. Details of the Meeting are provided below. Appointment of Board and Executive At the Meeting, shareholders voted in favour of Erdene management’s n ...

SAN DIEGO, June 20, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025.  Tempus purports to be provide Artificial Intelligence ("AI") enabled precision medicine solutions.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robbins LLP is Investigating Allegations th ...

Group 1 - A class action has been filed against Reddit, Inc. on behalf of investors who purchased securities between October 29, 2024, and May 20, 2025 [1] - The allegations include that Reddit misled investors about reduced user traffic due to changes in Google Search's algorithm and features, which led to a significant decline in traffic to the Reddit website [2] - The complaint states that the defendants were aware that increased search queries for "Reddit" were due to users finding answers directly on Google, rather than intending to visit Reddit, which contributed to the misleading public statements [2] Group 2 - Shareholders may be eligible to participate in the class action and can contact Robbins LLP for more information on serving as lead plaintiff [3] - The representation in the class action is on a contingency fee basis, meaning shareholders will not incur fees or expenses [4] - Robbins LLP has been dedicated to helping shareholders recover losses and improve corporate governance since 2002 [4]

Activist investor Barington Capital Group joins a growing chorus of dissatisfied Victoria's Secret VSCO shareholders.What Happened: The firm now holds more than 1% of the lingerie retailer's stock and plans to increase its position.Its campaign follows a sharp stock decline—more than 50% year-to-date. Victoria's Secret's market value slashed to about $1.5 billion. That's a steep drop from the $6.5 billion valuation it commanded after its 2021 split from Bath & Body Works Inc. BBWI.Also Read: Victoria’s Secr ...

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired Reckitt Benckiser Group PLC American Depository Shares (ADSs) between January 13, 2021, and July 28, 2024, alleging that the company misled investors regarding the safety of its Enfamil baby formula [1][2]. Allegations - The lawsuit claims that Reckitt failed to inform investors and consumers about the increased risk of necrotizing enterocolitis (NEC) in preterm infants consuming its cow's milk-based formula, Enfamil, and the potential negative impact on sales and legal exposure [2]. - A jury in Illinois awarded $60 million in a case against Mead Johnson, finding negligence related to the same NEC risk, which led to a significant drop in Reckitt's ADS price [3]. - Following a similar case in Missouri, where Abbott Laboratories was found liable for NEC, Reckitt's ADS price also experienced a notable decline [4]. Next Steps - Shareholders interested in participating in the class action must file a motion for lead plaintiff by August 4, 2025, with the option to remain an absent class member if they choose not to take action [5].